Vystar Corp (VYST)

[Wolverine19]

DaVita can be a huge part of Vystar Corps future

DaVita Inc. (DVA - Free Report) is gaining prominence in the MedTech space, courtesy of its incessant efforts to upgrade services, global expansion initiatives and acquisitions. The company has a market capitalization of approximately $9.80 billion.

Factors to Boost DaVita

DaVita has been steadily expanding in international markets. In the last few years, the company has strengthened its position in the emerging and developing markets of Brazil, China, Colombia, Germany, India, Malaysia, the Netherlands, Poland, Portugal and Saudi Arabia through strategic alliances as well as acquisitions of dialysis centers.

These strategic efforts are expected to help DaVita deliver more efficient patient care. Currently, DaVita is seeking to expand in major European and Asian countries via acquisitions and partnerships. In the fourth quarter, international dialysis patient service and other revenues totaled $124 million, up 30.5% year over year.

In the United States, DaVita has witnessed strong demand of dialysis services in recent times. In the fourth quarter of 2018, the company provided dialysis services at 2,905 outpatient dialysis centers, of which 2,664 centers were located in the United States and 241 in nine countries outside the country. Notably, fourth-quarter U.S. dialysis and related lab services’ revenues grossed $2.63 billion, up 10% from the prior-year quarter.

Which Way Are Estimates Headed?

For 2019, the Zacks Consensus Estimate for revenues is pegged at $11.60 billion, up 1.7% year over year. For adjusted earnings, the same is pinned at $4.42, up 23.8% year over year.
https://www.zacks.com/stock/news/356474/heres-why-investors-should-hold-davita-dva-stock-now

VYST